Status:
UNKNOWN
Change in LVEF Following Transcatheter Mitral Edge-To-Edge Repair
Lead Sponsor:
Rabin Medical Center
Conditions:
Mitral Regurgitation
Eligibility:
All Genders
Up to 120 years
Brief Summary
Little is known regarding the impact of transcatheter mitral valve edge-to-edge repair (TEER) on the acute changes in left ventricular ejection fraction (LVEF) and the effect of an acute reduction in ...
Detailed Description
Following surgical mitral valve repair for primary mitral regurgitation (MR), improved left ventricular (LV) and left atrial remodeling was demonstrated. However, little is known regarding the impact ...
Eligibility Criteria
Inclusion
- \-
Exclusion
- patients who are taken immediately to surgery following the procedure
- those who did not have echocardiographic information in the first 30 days post TEER
- patients who have undergone combined mitral and tricuspid repair
- severe non-cardiovascular diseases such as systemic infection or malignancy
- cardiogenic shock presenting at baseline
Key Trial Info
Start Date :
August 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2022
Estimated Enrollment :
4000 Patients enrolled
Trial Details
Trial ID
NCT05311163
Start Date
August 1 2021
End Date
August 1 2022
Last Update
April 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rabin Medical Center
Petah Tikva, Central District, Israel, 49100